Cti Biopharma reported $31.21M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Applied Genetic Technologies AGTC:US $ 13.58M 4.86M
Baxter International BAX:US $ 3395M 149M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Cti Biopharma CTIC:US $ 31.21M 6.18M
Cytori Therapeutics CYTX:US $ 5.12M 1.19M
Eli Lilly And LLY:US $ 5277.9M 127.8M
Geron GERN:US $ 28.05M 749K
Mirati Therapeutics MRTX:US $ 182.57M 2.36M
Northwest Biotherapeutics NWBO:US 21.69M 9.41M
Novartis NOVN:VX 10.86B 895M
Novartis NVS:US 10.86B 895M
Seattle Genetics SGEN:US $ 630.61M 71.1M
Teva Pharmaceutical Industries TEVA:US 4.74B 361M
YTE INCY:US $ 656.97M 40.27M